E-Medicare Pharma
Online Medicine Pharmacy
0.00$
Deucrava (Deucravacitinib) 6 mg is a medication used in the treatment of moderate to severe plaque psoriasis, a chronic autoimmune skin condition characterized by red, scaly patches on the skin. It belongs to a class of drugs known as Janus kinase (JAK) inhibitors, which work by blocking the activity of specific enzymes involved in the inflammatory response. Deucrava 6 mg offers a targeted therapy option for patients with psoriasis, helping to reduce skin inflammation and improve symptoms.
1. Indications:
Deucrava (Deucravacitinib) 6 mg is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
2. Pharmacology:
Deucrava (Deucravacitinib) 6 mg exerts its pharmacological effects by selectively inhibiting Janus kinases (JAKs), particularly JAK1, JAK2, and Tyrosine kinase 2 (TYK2). By blocking these enzymes, Deucrava interferes with the signaling pathways involved in the immune response, thereby reducing inflammation and slowing down the abnormal cell growth associated with psoriasis.
3. Dosage and Administration:
The recommended dosage of Deucrava (Deucravacitinib) 6 mg is one tablet taken orally once daily, with or without food. Treatment should be continued as long as the patient experiences clinical benefit and tolerates the medication well. Dose adjustments or discontinuation may be necessary based on individual patient response and tolerability.
4. Interaction:
Deucrava (Deucravacitinib) 6 mg may interact with other medications, including:
Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.
5. Side Effects:
Common side effects associated with Deucrava (Deucravacitinib) 6 mg may include:
Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.
6. Precautions and Warnings:
Before using Deucrava (Deucravacitinib) 6 mg, patients should be aware of the following precautions:
7. Overdose Effects:
In case of overdose with Deucrava (Deucravacitinib) 6 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Deucrava overdose, and patients should seek immediate medical attention if overdose is suspected.
Generic Name: | Deucravacitinib |
---|---|
Theraputic Category: | Anti-Cancer |
Pack Size: | 30’s |
Previous Product
Next Product
Begin your journey to better health . Join now to unlock exclusive tips and insights sent straight to your inbox, empowering you to embrace a healthier lifestyle each and every day.
Online Medicine Pharmacy
+8801929123476 emedicarepharma@gmail.com
65, mymansingh High-way, Dhaka-1230, Bangladesh